Basiliximab and infliximab for the treatment of steroid-refractory Crohn's disease

American Journal of Gastroenterology

Volumn 103, Issue 10, 2008, Pages 2665-

  Price, Michelle ^a   Probert, Christopher S J ^a   Creed, Tom ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; INFLIXIMAB; PREDNISOLONE; SALAZOSULFAPYRIDINE; STEROID;

ABSENCE OF SIDE EFFECTS; CASE REPORT; CROHN DISEASE; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; LETTER; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE DRUG DOSE; SYMPTOMATOLOGY;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RECOMBINANT FUSION PROTEINS;

EID: 53149131713     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2008.02074_14.x     Document Type: Letter

References (4)

1. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-alpha for Crohn's disease. N Engl J Med 1997 337 : 1029 36.
2. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005 353 : 2462 76.
3. Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997 350 : 1193 8.
4. Creed TJ, Probert CSJ, Norman MN, et al. Basiliximab for the treatment of steroid-resistant ulcerative colitis: Further experience in moderate and severe disease. Aliment Pharmacol Ther 2006 23 : 1435 42.